| Features: oral antidiabetic agent, | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Metformin is a pleiotropic drug: attributed to its action on AMPK Metformin is a biguanide drug used primarily for type 2 diabetes. Mechanistically, it is best described as a bioenergetic modulator: partial inhibition of mitochondrial respiration can raise AMP/ADP, engage AMPK, and suppress mTORC1 signaling; systemically it reduces hepatic gluconeogenesis and can lower insulin/IGF-1 growth signaling. In oncology, observational studies suggested improved outcomes in some settings, but randomized trial data are mixed (e.g., large adjuvant breast cancer data did not show broad benefit overall). Long-term use can be associated with vitamin B12 deficiency, and prescribing requires attention to renal function due to rare lactic acidosis risk in predisposed states. Metformin directly(partially) inhibits Complex I of the electron transport chain (ETC) in mitochondria. This inhibition decreases mitochondrial ATP production and forces cells to rely more on glycolysis for energy. Cancer cells, especially those with high energy demands, may be particularly sensitive to a drop in ATP levels. The inhibition of Complex I also increases the AMP/ATP ratio, setting the stage for the activation of downstream energy stress pathways. AMPK activation results in the inhibition of the mammalian target of rapamycin (mTOR) pathway, a central regulator of protein synthesis and cellular growth. mTOR inhibition reduces cell proliferation and limits tissue growth, which can slow tumor progression. Metformin reduces circulating insulin levels, which in turn can decrease the activation of the insulin and insulin-like growth factor-1 (IGF-1) receptor pathways. ETC Inhibitors: Drugs that directly inhibit specific ETC complexes (e.g., Complex I inhibitors like metformin or phenformin) can increase electron leakage and ROS production.(dose- and context-dependent, and not consistent) -known as mild OXPHOS inhibitor(Complex I modulator)
Time-Scale Flag (TSF): P / R / G
|
| Source: |
| Type: |
| Glycogen • Many tumors, especially under hypoxic or nutrient-deprived conditions, reprogram their metabolism to store glycogen as an energy reserve. • Increased glycogen accumulation can serve as a survival mechanism that helps cancer cells endure metabolic stress, which, in turn, may be associated with more aggressive behavior. • Prognosis: – In certain cancers (e.g., certain glioblastomas, pancreatic cancers), high intratumoral glycogen content has been associated with adaptation to hypoxia and resistance to therapy. – Such adaptations often correlate with a poorer prognosis, as the glycogen reservoir helps support tumor progression under adverse conditions. Frequently increased (accumulated) in tumors exposed to hypoxia, nutrient deprivation, or intermittent perfusion. Glycogen accumulation in cancer marks a stress-adapted metabolic state. It functions as an internal energy and redox buffer that enables tumors to survive hypoxia and treatment-induced shocks. |
| 5795- | MET, | Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Diabetic, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:11 Target#:1192 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid